

1 **The Dynamic Genetic Atlas of 122 Gestational**

2 **Phenotypes**

3

4 Siyang Liu^{1*#}, Hao Zheng^{1,2,3*}, Yuqin Gu^{1,3*}, Zijing Yang^{1,2*}, Yanhong Liu¹, Yuandan

5 Wei^{1,3}, Xinxin Guo¹, Yanchao Chen¹, Liang Hu², Xiaohang Chen², Fuquan Zhang³,

6 Guo-Bo Chen⁴, Xiu Qiu⁵, Shujia Huang^{5#}, Jianxin Zhen^{3#}, Fengxiang Wei^{2,6#}

7 1. School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen,

8 Guangdong 518107, China

9 2. The Genetics Laboratory, Longgang District Maternity and Child Healthcare

10 Hospital of Shenzhen City, Shenzhen, Guangdong, 518172, China

11 3. Central Laboratory, Shenzhen Baoan Women's and Children's Hospital, Shenzhen,

12 Guangdong 518102, China

13 4. Center for Productive Medicine, Department of Genetic and Genomic Medicine,

14 Clinical Research Institute, Zhejiang Provincial People's Hospital, People's

15 Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang, China

16 5. Division of Birth Cohort Study, Guangzhou Women and Children's Medical Center,

17 Guangzhou Medical University, Guangzhou, 510623, China

18 6. Longgang Maternity and Child Institute of Shantou University Medical College,

19 Shenzhen, Guangdong, 518172, China

20 *: Those authors contribute equally as co-first authors

21 #: Correspondence can be addressed to

- 22 Siyang Liu liusy99@mail.sysu.edu.cn
- 23 Shujia Huang shujia.huang@bigcs.org
- 24 Jianxin Zhen jxzhen@qq.com
- 25 Fengxiang Wei haowei727499@163.com
- 26

27 **Abstract**

28 The gestational period, spanning approximately 40 weeks from fertilization to birth, is
29 pivotal in human reproduction. Monitoring the health of pregnant women and
30 newborns during this period involves systematic prenatal and postpartum
31 examinations, guided by indicators established under the national medical insurance
32 system, collectively termed gestational phenotypes. However, our understanding of
33 the genetic basis of these phenotypes and their intricate relationship with maternal
34 long-term health outcomes remain markedly limited. We conducted comprehensive
35 genetic investigations into 122 gestational phenotypes among 121,579 Chinese
36 pregnancies. These phenotypes included anthropometric metrics, comprehensive
37 blood biomarker measurements, and common gestational complications and outcomes.
38 We identified 3,845 genetic loci, 1,385 of which are novel. Our analyses revealed
39 gestation-specific genetic effects, ranging from proportion 0% to 100% for 23
40 phenotypes, highlighting genes and pathways predominantly enriched in response to
41 hormones, growth and immune function. Longitudinal trajectory genome-wide
42 association study (GWAS) analyses of repeated measures across 24 complete blood
43 cell phenotypes revealed that 17.8% of the genetic variants exhibited significant
44 interactions with gestational timing across five gestational and postpartum periods.
45 Two-sample univariable and multivariable Mendelian Randomization (MR) analyses
46 of 220 mid- and old-age phenotypes suggested causal associations between
47 gestational phenotypes and the risk of chronic diseases in later life. These findings
48 provide initial insights into the genetic foundations of human gestational phenotypes
49 and their relationship with long-term health, laying a basis for advanced population
50 health during gestation.

51

52

53 **Introduction**

54 Women's reproductive, maternal, newborn, child, and adolescent health are
55 fundamental aspects of human health development and the key drivers of future
56 population and social progress^{1,2}. Amid the global trends of population aging and
57 declining fertility rates^{3,4}, maternal and child health has increasingly emerged as a
58 critical global public health concern. Particularly noteworthy is the gestational period,
59 starting from fertilization, to birth over approximately 40 weeks, is a crucial phase
60 during which the developing organism undergoes substantial growth and
61 differentiation, while the pregnant individual experiences various physiological
62 changes to support the fetus^{5,6}. Given the importance of this period, the health of
63 pregnant women and newborns is monitored through a set of systematic and timed
64 prenatal and postpartum examinations manipulated via the national medical insurance
65 system. These indicators encompass anthropometric metrics, a series of blood and
66 urine measurements and prenatal tests, forming the basis for diagnosing pregnancy
67 disorders and forecasting birth outcomes, collectively making up the gestational
68 phenotypes (**Fig. 1 and Supplementary Table 1**).

69
70 Despite the critical nature of the gestation period, the genetic underpinnings
71 underlying the gestational phenotypes and their connections to later age health
72 outcomes remain poorly understood. Of the 122 gestational phenotypes, only 29 have
73 been explored in previous GWAS studies (**Supplementary Table 1**), and 11 were
74 part of our earlier work⁷⁻⁹. While extensive genetic studies have been conducted on a
75 variety on various quantitative phenotypes in the general population^{10,11}, few have
76 addressed the distinct genetic basis of phenotypes during the gestation^{8,9,12}, and the
77 time-dependent genetic effects during this period remain largely unknown.
78 Additionally, despite observational studies have linked gestational status to maternal
79 older age health status¹³⁻¹⁶, evaluations of the causal effects of the spectrum of
80 gestational phenotypes, which usually collected earlier in life, on later age health

81 status have not yet been achieved, hindering the potential for early screening of
82 diseases for women typically aged 20 to 40.

83

84 To address this gap, we collected data on 122 prenatal and postnatal screening
85 indicators and non-invasive prenatal test (NIPT) sequencing data from 121,579
86 unrelated pregnant women (mean age 30 ± 4). We posed the following questions: (1)
87 What are the genetic determinants for these gestational phenotypes and what is their
88 heritability? (2) Do pregnancy-specific genetic effects exist, and which genes exhibit
89 these effects? (3) Are there gene-by-environment ($G \times E$) interactions for the genetic
90 loci associated with gestational phenotypes? (4) What are the causal relationships
91 between gestational phenotypes and maternal long-term health? To address these
92 questions, we conducted a large-scale genome-wide association study (GWAS) using
93 our developed analytical protocol^{7,17}, constructing an atlas of quantitative and
94 qualitative trait loci and replicating our findings in external cohorts. We investigated
95 patterns of genetic loci with differential effects during pregnancy and non-pregnancy
96 using a Bayesian clustering algorithm, and examined $G \times E$ effects through repeated
97 sampling of the same phenotypes during pregnancy using regression models. Finally,
98 we used our atlas to estimate potential causal relationships between gestational
99 phenotypes and 220 phenotypes in BioBank Japan (mean age 63 years), mimicking an
100 impact of the gestational phenotypes over the long-term health outcomes¹⁰ (**Fig. 1**).

101

102 **Results**

103 **Study design**

104 We collected NIPT sequencing data and 122 comprehensive pregnancy screening
105 measurements, including biomarkers and electronic medical records, from 121,579
106 Chinese pregnancies who participated in routine obstetric examinations at two
107 hospitals in Shenzhen City. We categorized the 88 gestational phenotypes into nine
108 molecular test categories: Blood lipid (N=2), Glycemic (N=6), Blood routine (N=32),

109 Infection (N=14), Kidney (N=3), Liver function (N=8), Thyroid function (N=4), Tang
110 screening (N=16) and NIPT screening (N=3) (**Fig.1, Supplementary Table 2**).
111 Additionally, we included 34 phenotypes in three categories of electronic medical
112 records: Basic information such as maternal height, weight, blood pressure (N=7),
113 Gestational disorders (N=21) and Birth outcomes (N=6) (**Fig. 1, Supplementary**
114 **Table 3**). Sample sizes for each phenotype ranged from 12,024 (gestational diabetes
115 mellitus with medication in Glycemic) to 115,872 (trisomy 18 risk score in NIPT
116 screening). The distribution of all quantitative gestational phenotypes and the
117 prevalence of common gestational comorbidities were highly consistent between the
118 two hospitals (**Supplementary Table 4-5, Supplementary Fig. 1-2**).

119
120 All participants underwent NIPT as part of standard prenatal screening in Shenzhen.
121 We applied our estimated protocol to infer and impute genotypes, estimate family-
122 relatedness, infer population structure, and conduct GWAS. More details about the
123 analyses are provided in the **Methods** section.

124

125 **3,845 genetic associations with 122 gestational phenotypes**

126 Using the collected phenotype data and NIPT genotypes, we performed GWAS for
127 the 122 gestational phenotypes from Baoan and Longgang hospitals, respectively,
128 followed by a fixed-effect meta-analysis across 12.6 million genetic markers
129 (**Supplementary Table 6**). Linkage disequilibrium (LD) score intercepts were
130 between 0.94 and 1.10 for all 122 phenotypes (**Supplementary Table 7**), which
131 suggested that population structure in our analysis was well controlled. Besides the
132 conventional genome-wide significant threshold ($P < 5 \times 10^{-8}$), we set a stricter study-
133 wide significant threshold to $P = 4.1 \times 10^{-10}$ ($P < 5 \times 10^{-8} / 122$) after Bonferroni
134 correction for multiple testing. After GCTA conditional and joint analysis¹⁸, we
135 identified 4,309 independent signals in 3,242 loci associated with at least one
136 phenotypes ($P < 5 \times 10^{-8}$) among nine categories (**Supplementary Table 8**), where

137 2,942 signals in 1,999 loci reached study-wide significance ($P < 4.1 \times 10^{-10}$) (**Fig. 2,**
138 **Supplementary Table 9**). The highest number of loci were found in the blood routine
139 category among all the categories, and the phenotype with the highest number of loci
140 was platelet-large cell ratio (P_LCR) (**Fig. 2, Supplementary Table 9**). Within the
141 three categories of basic information, birth outcomes and gestational disorders, we
142 found 367 independent signals in 279 loci ($P < 4.1 \times 10^{-10}$) and 718 independent
143 signals in 603 loci ($P < 5 \times 10^{-8}$) (**Supplementary Table 10-11**).

144
145 Genetic effect estimations are highly consistent between the two hospitals with
146 squared Pearson's correlation coefficient R^2 greater than 0.76 for nine categories of
147 quantitative traits and R^2 greater than 0.12 for three categories of qualitative traits
148 (**Supplementary Fig. 3**). Only 369 out of 4,309 (8.5%) loci associated with the nine
149 categories of gestational phenotypes and 74 out of 718 (10.3%) associated with the
150 three categories of gestational phenotypes exhibited statistical heterogeneity
151 ($P_{\text{het}} < 0.05$) (**Supplementary Table 8-11**). We also performed two replication studies
152 comparing genetic effect estimates with independent cohorts to evaluate the
153 robustness of effect estimates in our study. In replication study I, assuming maternal
154 height is not influenced by a gestational status, we compared genetic effect estimates
155 of maternal height-associated variants with that estimated in the Taiwan Biobank with
156 the GWAS summary statistic for maternal height in this study¹⁹. The genetic effect
157 estimates are highly consistent between our study and the Taiwan Biobank study with
158 $R^2 = 0.93$ (**Supplementary Fig. 4**). There were 121 variants with P values less than
159 the Bonferroni correction threshold ($P < 2.79 \times 10^{-4}$, 66.9%), and 166 variants with P
160 value less than 0.05 (91.7%) (**Supplementary Fig. 4, Supplementary Table 12**). In
161 replication study II, we compared the genetic effects with an independent cohort
162 (NIPT PLUS pregnancy cohort), which is our additional collection of maternal check-
163 up data from 5,733 pregnant women (**Methods**). Using *two-sample t-test*, 4,059 of the
164 4,804 variants of the 103 phenotypes with data in NIPT PLUS cohort had consistent

165 genetic effect size in independent cohort (84.5%) (**Supplementary Fig. 5,**
166 **Supplementary Table 13**). Of the 3,198 variants that were study-wide significance
167 within the study, 2,786 variants had consistent genetic effect (87.1%)
168 (**Supplementary Table 13**). The above results indicate high fidelity of the GWAS
169 findings and genetic effect estimates in this study.

170

171 **1,385 novel genetic associations**

172 Among the 122 gestational phenotypes, 29 were previously investigated among
173 pregnant women and 70 were investigated in the general populations
174 (**Supplementary Table 1**). After comparison with the GWAS Catalog²⁰ of previously
175 reported associations with the same or similar phenotypes in either the pregnant or the
176 general populations (**Methods**), 1,189 of the 3,242 loci surpassing the genome-wide
177 threshold (**Supplementary Table 8**), and 651 of the 1,999 loci surpassing the study-
178 wide threshold were novel among nine categories (**Supplementary Table 9**). Among
179 the three categories, 196 of the 603 loci surpassing the genome-wide threshold, as
180 well as 64 of the 279 loci surpassing the study-wide threshold were novel
181 (**Supplementary Table 10-11**). Notably, 5,483 and 5,194 functional variants
182 including missense and nonsense variants ($P < 5 \times 10^{-8}$) were found for the 3,242
183 genome-wide significant loci and the 1,999 study-wide significant loci ($P < 4.1 \times 10^{-10}$),
184 respectively (**Supplementary Table 14-15**). 256 study-wide newly discovered loci
185 with at least one functional variant were illustrated in **Fig. 2**.

186

187 Among the 651 study-wide significant novel loci associated with the nine
188 quantitative trait categories, 114 were associated with multiple gestational
189 phenotypes (**Supplementary Table 16**). The genes mapped in these 114
190 pleiotropic loci were significantly enriched in GO pathway such as response to
191 hormones, compared to an enrichment of more basic cellular processes such as
192 hemostasis, regulation of cell-cell adhesion for genes without pleiotropy

193 (Supplementary Fig. 6). Protein-protein interaction network (PPIN) analysis
194 suggests that *IL6* involved in immune responses, *ESRI* related to hormone response
195 and *IGF1* and *EGF* related to cell growth and development are the most essential
196 hub genes (Supplementary Fig. 7, Supplementary Table 17). The *ESRI*
197 associated with nine gestational phenotypes, is among the genetic loci with the
198 broadest pleiotropy (Supplementary Fig. 8, Supplementary Table 16). The
199 estrogen receptor 1, *ESRI* is a key gene for embryo implantation and affects uterine
200 natural killer cell motility and thus vascular remodeling in early pregnancy and the
201 placenta²¹⁻²³. This is consistent with our findings of variants in *ESRI* were
202 significantly associated with leukocytes (lymphocyte percentage (LYM_P),
203 monocyte absolute value (MON), neutrophils absolute value (NEUT) and white
204 blood cell count (WBC)) during pregnancy (Supplementary Fig. 8,
205 Supplementary Table 16). In addition, *ESRI* is first identified to be strongly
206 associated with triglyceride (TG), oral glucose tolerance test 0 hour (OGTT0H), red
207 blood cell count (RBC) and hematocrit (Hct) in our study. Several other genetic
208 loci exhibiting the highest level of pleiotropy in gestational phenotypes include
209 *ELOVL5* (encoding ELOL fatty acid elongase 5) associated with beta human
210 chorionic gonadotropin (FHCG), pappalysin (PAPP) and Tang screening scores of
211 Trisomies 21 and 18, *SLC35A1* (solute carrier family 35 member A1) associated
212 with FHCG, Tang screening score of Trisomy 21 and free thyroxine (FT4) which
213 are important for pregnancy (Supplementary Table 16).
214
215 We particularly examined a number of phenotypes that had been very poorly
216 studied, such as the screening phenotypes for fetal trisomy. Combined maternal
217 serum Tang and NIPT screening along with fetal ultrasound testing are used to
218 screen for the risk of fetal trisomy^{24,25}, so these phenotypes are essential for the
219 gestational period. For the NIPT screening scores for T21, T18 and T13, we found
220 26, 35 and 31 quantitative trait loci ($P < 4.1 \times 10^{-10}$) (Supplementary Table 9,

221 **Supplementary Fig. 9**). Notably, intronic variants, eQTLs for *PANXI*, located in
222 chromosome 11, a cell membrane factor highest expressing in human oocytes,
223 eight-cell embryos, and the brain were significantly associated with all three scores
224 in the NIPT screening. Abnormal Pannexin 1 (*PANXI*) has been previously linked
225 to a type of infertility called “oocyte death” in family study^{26,27}. In our study, all the
226 variants associated with a decreasing *PANXI* increases the NIPT screening scores,
227 suggesting higher trisomy risk. Meanwhile, variants near and within *PADI4*
228 (peptidyl arginine deiminase 4) were similarly associated with these three
229 phenotypes, and the gene is associated with neutrophil extracellular trap formation
230 (NETosis) and is important for immune regulation during pregnancy²⁸⁻³⁰. In
231 addition, TNF superfamily member 13b (*TNFSF13B*) and ubiquitin specific
232 peptidase 3 (*USP3*) are associated with two of these scores, and they both play a
233 role in the innate immune response^{31,32}.

234

235 **Heritability and correlation of gestational phenotypes**

236 To characterize the heritability of the 122 phenotypes, we applied LD Score
237 regression (LDSC)³³. Among all the phenotypes, maternal serum vitamin B12 levels
238 had the highest SNP heritability of 43.97% (**Supplementary Table 7,**
239 **Supplementary Fig. 10**). The phenotype with lowest SNP heritability was gestational
240 thrombocytopenia, at 0.0045% (**Supplementary Table 7, Supplementary Fig. 10**).
241 Although the heritability of vitamin B12 in the UK Biobank (UKB) ($h^2=0.00953$,
242 $se=0.0143$) is low³⁴, there is a study of white British twin women that showed a 56%
243 heritability of serum vitamin B12³⁵. We hypothesize that the reason for the disparity
244 with UKB is the effect of racial differences and gender of the population.

245

246 Phenotypic and genetic correlations were calculated for a total of 88 quantitative
247 phenotypes in nine categories put together (**Supplementary Fig. 11, Supplementary**
248 **Table 18-19**,). The two heatmaps were basically symmetric along the red diagonal

249 line suggesting that substantial phenotypic variability derived from the genetic
250 variability (**Supplementary Fig. 11**). Tightly correlated phenotypic domains were
251 clustered within categories, while significant and strong genetic correlations also
252 occur across categories.

253

254 **Gestation-specific genetic effect**

255 Gestational phenotypes may exhibit pregnancy-specific genetic effects distinct from
256 the same phenotypes outside pregnancy. For 23 out of the 122 phenotypes
257 investigated, including maternal height, we obtained GWAS data in a non-pregnant
258 cohort from the Taiwan Biobank (n = 92,615, age 30-70, southern Chinese ancestry)
259 ¹⁹. Genetic correlations for the same phenotype between the two datasets are all
260 significant ranging from 0.18 to 0.94 (**Supplementary Table 20**). Correlations of
261 genetic effect of NIPT lead SNPs are high between our study and the Taiwan Biobank
262 study with genetic effect R^2 ranging from 0.001 to 0.99 (**Supplementary Fig. 12**,
263 **Supplementary Table 21**). 900 genetic signals were present with study-wide
264 significance for the 23 phenotypes and 792 signals have genetic effect information in
265 both our and the Taiwan studies (**Supplementary Table 22**).

266

267 We then applied a Bayesian clustering algorithm³⁶ combined with colocalization
268 analysis to explore whether there exists genetic effects that are predominantly
269 influenced by pregnancy compared to non-pregnancy population. Model parameters
270 are detailed in **Supplementary Table 23 and Methods**. Genetic loci associated with
271 each of the gestational trait were categorized into two groups: general and pregnancy-
272 specific, with the remaining loci denoted as unclassified. In total, we have identified
273 138 genetic signals exhibiting pregnancy specific genetic effects (**Supplementary Fig.**
274 **13, Supplementary Table 24**). The general variants indicates that the genetic effects
275 were shared with non-pregnancy phenotypes, and pregnancy-specific cluster indicates
276 the ones dominated by mainly gestational phenotypes. In total, we found 138 out of

277 the 792 signals exhibiting pregnancy-specific effects (17.4%), while 381 signals
278 demonstrating shared genetic effect (48.1%) and 273 remains uncertain (34.5%).
279 When ranking these 23 phenotypes by the proportion of pregnancy-specific loci
280 among all loci, alpha fetoprotein levels (AFP_S2) or its adjusted form, the alpha-
281 fetoprotein multiples-of-median (AFPMOM_S2) in second trimester screening have
282 the highest proportion of variants exhibiting pregnancy-specific genetic effects,
283 followed by two biomarkers for liver function including alanine transaminase (ALT)
284 and albumin (ALB) (**Fig. 3A, Supplementary Table 24**). Contrastly, the lowest
285 proportion of pregnancy specific variants were observed for maternal height and first
286 systolic blood pressure measurements, consistent with our perception that pregnant
287 women's height is largely unchanged during pregnancy and blood pressure stays
288 stable in early pregnancy.

289

290 Pathway enrichment analyses of the pregnancy-specific, general and overall genetic
291 loci were summarized in **Supplementary Fig. 14**. We further conducted a pathway
292 enrichment analyses using genes falling within the pregnancy-specific effect and the
293 general effect clusters to test whether some pathways may significantly differ between
294 the two clusters of genes (two-tailed chisq or fisher exact test, $P < 0.05$) (**Fig. 3B,**
295 **Supplementary Table 25**). Among these top 20 significant pathways for the
296 pregnancy-specific genetic loci, there are a variety of pathways that have significantly
297 different gene proportion on both sides, such as the retinoid metabolism and transport,
298 Wnt signaling pathway and pluripotency and regulation of protein catabolic process
299 that only contains pregnancy-specific loci (**Fig. 3B**). In addition, pathways that
300 demonstrated nominally significance include GO pathways of responses to hormone,
301 glucose homeostasis and regulation of lymphocyte proliferation; KEGG pathways of
302 breast cancer, WikiPathways of pathways in cancer and adipogenesis and Reactome
303 gene sets of signaling by nuclear receptors (**Supplementary Table 25**). PPI network
304 hub gene analyses weighting the genes by degree suggests that the most

305 distinguishing hub genes are similar to the genes that were associated with multiple
306 gestational phenotypes, including the estrogen receptor (*ESR1*), insulin like growth
307 factor 1 (*IGF1*) and interleukin 6 (*IL6*) (**Supplementary Fig. 15, Supplementary**
308 **Table 26**). These findings suggests that hormone, growth and development mediators
309 and immune regulations are playing an essential role for starting the gestation process.
310

311 **G (genetics) by T (time) interaction across gestation and postpartum** 312 **period**

313 Among the 122 gestational phenotypes, the 24 phenotypes belonging to the blood
314 routine category assayed by the complete blood count (CBC)^{37,38} are repeatedly
315 assayed for a median number of 5 to 6 measurements in each of the two hospitals
316 (**Supplementary Fig. 16-17, Supplementary Table 27**), offering us an opportunity
317 to understand the patterns and biological meaning of potential longitudinal time-
318 varying genetic effect.

319
320 The changing trends of these 24 phenotypes during pregnancy were largely similar
321 between the two hospitals (**Supplementary Fig. 18-19**). Among the leukocyte-related
322 phenotypes, white blood cell (WBC), neutrophil counts (NEUT), and neutrophil
323 percentages (NEU_P) increased significantly during pregnancy. In addition,
324 lymphocyte (LYM) levels decreased, monocyte (MON) levels increased, eosinophils
325 (EOS) were essentially unchanged and basophils (BASO) fluctuated at average levels.
326 Red blood cell counts (RBC), hemoglobin (HGB) levels, hematocrit (Hct) and platelet
327 count (PLT) have a significant downward trend during pregnancy. All CBC
328 phenotypes changed greatly in the delivery and postpartum period, tending to return
329 to pre-pregnancy levels.

330
331 We investigated the longitudinal time-varying genetic effect following two steps. First,
332 we applied TrajGWAS³⁹ to identify genetic variants affecting the phenotypic mean

333 variability across the 24 CBC gestational phenotypes for each hospital, respectively.
334 By default, TrajGWAS³⁹ will also compute the effect of genetic variants affecting the
335 within-subject variability. Genetic variants affecting phenotypic mean and within-
336 subject variability (β_g and τ_g significant genetic variants) are shown in the
337 **Supplementary Fig. 20-27**. In total, we identified 645 variants associated with the
338 phenotypic mean reaching a genome-wide significance threshold in both hospitals (P
339 $< 5 \times 10^{-8}$). Secondly, we included a genotype dosage and gestational day interaction
340 term in the above TrajGWAS regression model for each hospital, testing the statistical
341 significance of the interaction effect size, similar to a locus-based genetic-by-time
342 ($G \times T$) analysis (**Methods**). After integrating the two hospital statistics via inverse-
343 weighted variance fixed effect meta-analysis, 115 out of 645 the variants (17.8%)
344 demonstrated significant interaction effect with gestational days ($P < 5 \times 10^{-8}$)
345 (**Supplementary Table 28**), while the rest of the 530 variants only affected the
346 phenotypic mean level but the interaction effects were not significant
347 (**Supplementary Table 29**). Among the 23 phenotypes, the percentage of variants
348 with significant $G \times T$ effects ranged from 5.4% to 47.8% (**Supplementary Table**
349 **30**).

350
351 To explore how genetic variants specifically change during the first, second, third
352 trimesters of pregnancy, delivery, and postpartum period, we performed localized
353 association studies of these 115 variants (**Methods, Supplementary Table 31**) and
354 found 79 out of the 115 variants exhibited non-overlapping 95% CIs for genetic effects
355 in at least two of the five periods (**Supplementary Table 31, Supplementary Fig.**
356 **28**). Therefore, we confirm that 79 out of the 645 variants (12.2%) demonstrated
357 substantial and significant changes of genetic effects across the gestation and
358 postpartum period. The 25 variants with the most significant $G \times T$ interaction effects
359 were demonstrated in **Fig. 4A**. 22 out of these 25 variants have strong expression
360 quantitative trait loci (eQTL) information (**Supplementary Table 31**). Taking the

361 gestational WBC (leukocyte) count as an example, the WBC count steadily increased
362 since the first trimester and reached its highest in the 3rd trimester and delivery (**Fig.**
363 **4B**). Among the 27 variants associated with WBC, eight variants (29.6%) exhibiting
364 significant $G \times T$ interaction. Among the eight variants, rs2270401 (17q21.1), a
365 strong eQTL for *GSDMA*, exhibited the most significant $G \times T$ interaction effect,
366 with genetic effects varied substantially across the five periods (first trimester:
367 $\beta=0.270$, $P=6.44 \times 10^{-491}$; second trimester: $\beta=0.396$, $P=1.62 \times 10^{-1223}$; third trimester:
368 $\beta=0.388$, $P=2.27 \times 10^{-1021}$; delivery: $\beta=0.257$, $P=2.06 \times 10^{-152}$; postpartum: $\beta=0.122$,
369 $P=6.48 \times 10^{-60}$) (**Fig. 4C, Supplementary Table 31**). The genetic effect of the
370 rs2270401-A allele was 3.33 times greater in the second trimester than in the
371 postpartum period. Genetic effect of the other seven loci also demonstrated a U-
372 shaped change across the five period (**Supplementary Fig. 28**). The WBC phenotypic
373 and genetic effect changes of the eight loci suggest these loci may play an essential
374 role in the rapid growth of leukocytes during pregnancy and postpartum.

375
376 We extracted genetic variants with significant versus non-significant genetic and
377 environmental interactions for enrichment analyses. Gene enrichment analysis for
378 each category of variants were summarized in **Supplementary Fig. 29**. In a chisq and
379 fisher exact test for testing significant difference of pathways with interaction effect
380 and those without, we found pathways enriched in regulation of phagocytosis,
381 engulfment, prefoldin mediated transfer of substrate to CCT/TriC, Heparan
382 sulfate/heparin (HS-GAG) metabolism, Gap junction, nerve development and lipid
383 modification (**Fig. 4D, Supplementary Table 32**). Different from the genes
384 harboring gestation-specific genetic effects, PPI network hub gene analyses weighting
385 the genes by degree suggests that the most distinguishing hub gene is Epidermal
386 Growth Factor (*EGF*) involved in cell growth and development and the GATA
387 binding protein 2 (*GATA2*) which involved in hematopoietic development
388 (**Supplementary Fig. 30, Supplementary Table 33**). This suggests that alterations

389 in the genetic effects of variants affecting blood cell levels during pregnancy are more
390 related to changes in cell activation and cytokines in pregnant women.

391

392 **Causal relationship with older-age phenotypes**

393 To explore whether gestational phenome may influence or correlated with the
394 occurrence of chronic diseases in mothers in the distant future, we first estimated
395 causal effects of the 122 gestational phenotypes on 220 phenotypes examined in the
396 BioBank Japan Study (BBJ)¹⁰ using two-sample, inverse variance weighted,
397 bidirectional MR and four additional two-sample approaches as sensitivity analyses.
398 After MR-PRESSO elimination of outliers⁴⁰, 73 significant potential causal
399 relationships were found for the 122 gestational phenotypes, using FDR q -value less
400 than 0.01 as false discovery rate (FDR) threshold with 1,764 non-collinear phenotypic
401 pairs and excluding Cochran's Q statistic or pleiotropy P -value less than 0.05, and
402 these causal relationships were not significant in the reverse MR (Methods). The
403 bidirectional causal effect estimates were presented in a network view in **Fig. 5A**,
404 with the forward MR effect estimates of 88 molecular phenotypes presented in **Fig.**
405 **5B and Supplementary Table 34** and the forward MR effect estimates of the other
406 34 phenotypes presented in **Supplementary Fig. 31 and Supplementary Table 35**.

407

408 We identified numerous previously known and unidentified potential causal
409 associations. Genetically predicated higher gestational BMI contributes to the most of
410 the older-age disorders and phenotypes in our study. It increasing liability of 13 older-
411 age disorders or phenotypes with the largest effects observed on chronic renal failure
412 (OR [95%CI]: 1.68 [1.42-2.00]), followed by several cardiovascular disorders such as
413 myocardial infarction, peripheral artery disease, chronic heart failure, unstable angina
414 pectoris, type 1 diabetes and cholelithiasis as well as five medication use of drugs and
415 three physical phenotypes, while gestational BMI slightly decreasing liability of two

416 older-age disorders including pneumothorax and pulmonary tuberculosis (**Fig. 5A,**
417 **Supplementary Fig. 31 and Supplementary Tables 35**).

418

419 In addition, our MR results suggest contribution of gestational blood lipid and
420 glycemic biomarkers causally associated with older-age disorders. For example,
421 genetically predicted elevated triglyceride levels in pregnant women is associated
422 with an increased risk of taking certain medications, such as the medication use of
423 antithrombotic agents (*OR* [95%CI]: 1.09 [1.06-1.12], $P=1.24\times 10^{-11}$) (**Fig. 5C,**
424 **Supplementary Table 34**). In addition, genetically predicted elevated 1h blood
425 glucose levels on the oral glucose tolerance test (OGTT1H) in pregnant women
426 increase the risk of peripheral arterial disease (PAD) (*OR* [95%CI]: 1.24 [1.13-1.37],
427 $P=1.24\times 10^{-5}$) (**Fig. 5D, Supplementary Table 34**), consistent with prior report of
428 glucose abnormalities as a risk factor for PAD⁴¹. Moreover, elevated levels of
429 genetically predicted OGTT1H also increase the risk of cataract (*OR* [95%CI]: 1.15
430 [1.09-1.21], $P=3.21\times 10^{-8}$) (**Supplementary Table 34**), which is in accordance with
431 the results of the animal model⁴².

432

433 Furthermore, our results also show that genetically increased infections increase
434 certain disease liability. For instance, genetically increased gestational hepatitis B
435 core antibody positive (HBcAb) increases the risk of gastric cancer (*OR* [95%CI]:
436 1.12 [1.06-1.19], $P=1.06\times 10^{-4}$), chronic hepatitis B infection (*OR* [95%CI]: 1.31
437 [1.15-1.49], $P=5.27\times 10^{-5}$) and hepatic cancer (*OR* [95%CI]: 1.24 [1.13-1.37],
438 $P=5.02\times 10^{-6}$) (**Fig. 5A, Supplementary Table 34**), revealing a potential causal
439 relationship between hepatitis B infection observed during pregnancy and
440 extrahepatic cancers. Moreover, genetically predicted quantitative levels of
441 cytomegalovirus IgG (CMV_IgG_quan) were found to be associated with an
442 increased risk of some cardiac diseases (angina pectoris: *OR* [95%CI]: 1.31 [1.16-
443 1.49], $P=1.28\times 10^{-5}$; stable angina pectoris: *OR* [95%CI]: 1.27 [1.16-1.40]; medication

444 use vasodilators used in cardiac diseases: *OR* [95%CI]: 1.26 [1.15-1.38]). This is
445 consistent with previous studies suggesting increased exposure to cytomegalovirus
446 infection is related to coronary artery and vascular atherosclerotic diseases^{43,44}. More
447 broadly, we found that genetically predicted increases in BMI during pregnancy were
448 associated with an increased risk of developing a variety of diseases, such as chronic
449 kidney failure (*OR* [95%CI]: 1.68 [1.42-2.00]) and myocardial infarction (*OR*
450 [95%CI]: 1.26 [1.17-1.35]) (**Fig. 5A, Supplementary Table 34, Supplementary Fig.**
451 **31**). In general, a less superior physiological state during pregnancy is likely to
452 threaten the future health of the woman.

453
454 The causal impact of the gestational phenotypes (collected from pregnancy women
455 with mean age of 30) may directly contribute to the later-age phenotypes (collected
456 from BBJ with ages ranging from 30 to 70) or the causal effect may be mediated
457 through the same phenotypes in a middle age period. To understand this process, we
458 utilized the previously analyzed IVs with pregnancy-specific and shared effects with
459 the 23 phenotypes shared with the Taiwan Biobank, we added GWAS data from the
460 Taiwan Biobank as a second exposure and conducted a multivariable MR (MVMR).
461 Using FDR q value as the threshold of significance (NIPT effect $q < 0.01$), we
462 identified a total of 45 significant causal effects of the gestational phenotypes on the
463 later-age outcomes even after adjusting for the genetic effects of the exposures in the
464 Taiwan Biobank. Among these, 40 effects have a q value > 0.05 in the Taiwan dataset
465 or having an opposite genetic effect compared to ones with the gestational phenotypes
466 suggesting substantial direct causal effects on the outcomes. The remaining 5 effects
467 have a nominally significant P and consistent effect direction in the Taiwan dataset,
468 indicating less strong direct causal effects of the gestational phenotypes on the later
469 age phenotypes (**Supplementary Table 40, Supplementary Fig. 32**). In addition,
470 there are 97 effects having a q value < 0.01 for the Taiwan while having an opposite
471 beta direction or a q value > 0.05 in the NIPT dataset, suggesting that the NIPT

472 effects on the outcome is primarily dominated by the middle and older age genetic
473 effects. Among the 40 out of the 143 effects (28.0%) with potential direct causal
474 effects, notable relationships include genetically predicted gestational AFP and
475 AFPMOM in the second trimesters is negatively associated with atopic dermatitis and
476 all types of white blood cell, while it is positively associated with thyroid disorders
477 such as Grave disease, Hashimoto thyroiditis as well as medication use thyroid
478 preparations, chronic sinusitis, Type 2 diabetes and medication use drugs in diabetes
479 (**Supplementary Fig. 32 A-B, Supplementary Table 40**). In addition, genetically
480 predicted albumin during pregnancy is negatively associated with chronic hepatitis B
481 infection and cirrhosis. AST and RBC from NIPT datasets are causally associated
482 with the related blood cell information in the BBJ (**Supplementary Fig. 32 C,**
483 **Supplementary Table 40**). We also compared the results of univariate MR between
484 the 23 gestational phenotypes and the Taiwanese phenotype, and the results have high
485 consistency with an R^2 of 0.79, consistent with the above statistics where the majority,
486 namely 97 versus 45 of the gestational phenotypic effects on outcomes through older-
487 age phenotypes, and through direct effects (**Supplementary Fig. 33, Supplementary**
488 **Table 41-42**).

489

490 **Discussion**

491 Our study represents the largest scale GWAS on gestational phenotypes to date and
492 provides the first insight into the dynamic genetic atlas of human gestational
493 phenotypes and their causal associations with older-age health conditions. Using
494 obstetric and NIPT genotype data from 121,579 pregnant women, we identified 3,845
495 genome-wide significant loci, of which 1,385 loci were novel to this study and the
496 majority of which consists of at least one function variant. More than 84.5% of the
497 genetic associations were replicated in independent cohorts. Genes associated with
498 multiple gestational phenotypes are enriched in response to hormones, compound
499 biosynthetic and multi-organism reproductive processes, and PPI network analysis

500 reveals that *IL6* involved in immune responses, *ESR1* related to hormone response
501 and *IGF1* and *EGF* related to cell growth and development are the most essential hub
502 genes, providing the first insights into the role of immune, hormone and cell growth
503 responses and the key gene players in gestational process from a human genetic
504 perspective, beyond previous insights achieved via metabolome of primate pregnancy
505 ⁵.

506

507 Notably, the genetic atlas of gestational phenotypes is dynamic, reflecting gestation-
508 specific $G \times E$ and gestation time-varying $G \times T$ interactions. Combining data from
509 the Taiwan Biobank and using Bayesian classification analysis, we identified
510 pervasive gestation-specific genetic effects that present in around 17.4% of the
511 genetic associations (138/792) with 23 gestational phenotypes, ranging from ~0% for
512 early pregnancy systolic blood pressure to 100% for alpha-fetoprotein in second
513 trimester. Genes containing gestation-specific genetic effect exhibit a predominant
514 enrichment in pathways involving cancer, response to hormones, lipid, vitamin and
515 glucose metabolisms, and cell growth and development. PPI network analysis
516 highlights *ESR1*, *IGF1* (but not *EGF*) and *IL6* as the most significant hub genes.

517

518 On the other hand, in a longitudinal trajectory GWAS analysis of repeated
519 measurements of 24 complete blood count (CBC) phenotypes, we found significant
520 $G \times T$ interactions present in 12.2% of the genetic variants (79/646) throughout the
521 five gestational, delivery and postpartum periods, with hub genes as *EGF* and *CATA2*
522 in the PPIN, and pathways enriched in regulation of cell growth activity, nerve
523 development and lipid modification.

524

525 Conditions during gestational period were deemed as unique opportunities for early
526 screening and prediction for late-onset chronic disease risk in women⁴⁵. Our results
527 suggest causal relationships between adverse gestational conditions and

528 cardiovascular disease, including obesity, dyslipidemia and dysglycemia. We also
529 found that genetically predicted blood glucose abnormalities during pregnancy were
530 associated with an increased risk of cataracts. Previous study has shown that pregnant
531 women with gestational diabetes mellitus, even if they do not have type 2 diabetes,
532 have an increased risk of developing cataracts⁴⁶. In addition, multivariable Mendelian
533 randomization results indicate that high AFP levels during pregnancy are likely to
534 lead to inflammation-related diseases and diabetes, adjusted for mid-life health status.
535 Thus, the state of pregnancy is related to women's health in the long term.

536

537 There are some limitations which are connected to future perspectives in our study.
538 First, although the current study represents the largest GWAS for the majority of the
539 phenotype, the current study participants are restricted to East-Asian participants, and
540 the genetic novel discoveries may be different among non-East-Asian population.
541 However, the study methods made available in this study provides a foundation for
542 expanding the participants from non-East-Asian ancestry, which is promising as NIPT
543 tests as well as pregnancy screening programs are undertaken globally around the
544 world. The future comparisons of European and East-Asian gestational phenotypes
545 may lead to new insights into the ethnic difference for gestational phenotypes and its
546 relationship to offspring's health⁴⁷. In addition, the cross-ancestral analysis will
547 facilitate fine-mapping and validation of the functional variants identified in this study.
548 Secondly, while we provide a dynamic view of the genetic atlas of the gestational
549 phenotypes based on a robust statistical framework, unravelling 12 to 17% of
550 gestation-specific genetic effects and time-varying genetic effects, unravelling novel
551 genes involved in immune and hormone response, and cell-growth and development
552 in determining phenotypic distribution specifically during gestation. How these genes
553 may influence and modulate how gestation initializes and progresses, and how they
554 might contribute to abnormal gestations requires further comparisons or investigations
555 in the patient-oriented study and more in-depth mechanistic study conditioning on the

556 findings in this study. Thirdly, beyond the genetic and causal relationships between
557 gestational phenotypes and broad human complex and older age phenotypes
558 investigated in our study, another important investigation will be the dissection of
559 fetal genetic and intrauterine effects on birth outcomes and offspring health
560 conditioning on the dynamic atlas presented here and expanding birth cohort genome
561 studies¹⁴.

562

563 The genetic discoveries in this study provides foundational insights into the dynamics
564 of genetic landscape of the human gestational period. As we continue to expand the
565 genomic data and methods, future efforts will be prioritized to combine the genetic
566 information to dissect the developmental origin of children and adult disorders and for
567 exploring health and risk prediction for women during the gestational time window.
568 These should be conducted in global efforts.

569

570

571 **Methods**

572 **Study population**

573 From 2017 to 2022, we recruited 121,579 pregnant women who performed maternity
574 checkups in Shenzhen Baoan Women's and Children's Hospital and Longgang District
575 Maternity and Child Healthcare Hospital of Shenzhen City into our study. Pregnant
576 women received prenatal and postnatal serum biomarkers testing and non-invasive
577 prenatal testing (NIPT) in the first or second trimester or both of pregnancy. Maternal
578 genotypes were inferred from low-depth whole-genome sequencing data generated
579 from NIPT using our previously developed advanced methods⁷. In addition, we also
580 collected basic physical measurements of participants and their babies' birth outcomes.
581 The details of the number of participants in each test are presented in Supplementary
582 Table (**Supplementary Table 2-3**). The age distribution of pregnant women and the

583 prevalence of some gestational comorbidities in the two hospitals are shown in the
584 supplementary material (**Supplementary Table 4-5, Supplementary Fig. 1-2**).

585

586 We integrated all the obstetrical data, including genotypic and phenotypic data, to
587 explore the genetic and molecular risk factors underlying the phenotypic spectrum of
588 pregnant biomarkers. This study was approved by the Medical Ethics Committee of
589 the School of Public Health (Shenzhen), Sun Yat-sen University, Longgang District
590 Maternity and Child Healthcare Hospital of Shenzhen City, and Shenzhen Baoan
591 Women's and Children's Hospital. Data collection was approved by the Human
592 Genetic Resources Administration of China (HGRAC).

593

594 **Phenotype definition**

595 In the genome-wide association study (GWAS) analyzing gestational phenotypes, we
596 collected 122 maternal phenotypes in nine categories concerning Blood lipid (N=2),
597 Glycemic (N=6), Blood routine (N=32), Infection (N=14), Kidney function (N=3),
598 Liver function (N=8), Thyroid function (N=4), Tang screening (N=16) and NIPT
599 screening (N=3), as well as three categories including Basic information (N=7),
600 Gestational disorders (N=21) and Birth outcomes (N=6) (**Supplementary Table 2-3**).
601 For phenotypes with multiple measurements, we filtered out the record with the
602 earliest measurement date. In longitudinal genetic analyses, we retained all
603 measurements of complete blood count (CBC).

604

605 **Genotype imputation from Non-Invasive Prenatal Testing data and** 606 **quality control**

607 NIPT for fetal trisomy by sequencing maternal plasma free DNA (cfDNA) is new
608 genomic sequencing technology⁴⁸. Large-scale low-pass and mediate-coverage
609 sequencing data are available through NIPT. In our previous study, we demonstrated
610 that NIPT data can be used effectively for GWAS analysis⁷. Therefore, it is robust that

611 we use imputed NIPT data for genetic basis of prenatal and postnatal screening
612 indicators.

613

614 Genotype imputation from NIPT data was conducted by genotype likelihoods
615 imputation and phasing method using GLIMPSE software (version 1.1.1)⁴⁹ with
616 10,000 Chinese population high-depth sequencing genotype as reference panel⁵⁰. Loci
617 with minor allele frequency less than 0.001 were filtered in advance for reference
618 panel. To address confounding by population relatives, we excluded the duplicated
619 sequencing records of the same people from different pregnant times and kept the
620 highest sequencing depth.

621

622 **Family relatedness and principal component analyses**

623 PLINK⁵¹ (version 2.0) was used to select SNPs with an MAF of at least 5%. The
624 kinship was calculated based on the KING-robust kinship estimator. We used a cutoff
625 of approximately 0.354 to identify monozygotic twins and duplicate samples. In
626 addition, we applied PLINK⁵¹ (version 2.0) for principal component analyses (PCA)
627 both before and after genotype imputation. EMU⁵² (version 0.9) was used for PCA
628 specifically before genotype imputation.

629

630 **Variant annotation**

631 We performed variant annotation using Ensembl Variant Effect Predictor (VEP)
632 (version 101)⁵³, with indexed GRCh38 cache files (version 109). HGVS notations
633 were generated by primary assembled reference FASTA files for *Homo sapiens*. All
634 these data for annotation were pre-downloaded from the Ensembl FTP server
635 (<https://ftp.ensembl.org/pub/>). Since a variant may overlap with multiple transcripts,
636 we used the --pick option to assign one block of results to each variant based on a set
637 of VEP default criteria. For variants located in intergenic regions, we used the --

638 nearest option to identify the nearest gene to the protein-coding transcription start site
639 (TSS).

640

641 **Genome-wide association analysis and conditional analysis**

642 After quality control of the sequencing data and imputation of genotype from the
643 NIPT data, we conducted genome-wide association analysis using PLINK⁵¹ (version
644 2.0) to examine the association of the 122 phenotypes, assuming additive genotype
645 effects. For quantitative traits, we utilized linear regression model for GWAS, and for
646 qualitative traits, we used logistic regression model. To account for population
647 stratification, we considered some or all the following as covariates in the GWAS for
648 all phenotypes: maternal age, body mass index (BMI), gestational week at the time of
649 indicators measurement, and the top ten principal components. All GWAS covariates
650 were shown in the **Supplementary Table 6**.

651

652 Using the GWAS summary statistics from two hospitals, we performed meta-analyses
653 using METAL⁵⁴ (version 2011-03-25) with an inverse-variance weighted (IVW)
654 fixed-effect model. To visualize the meta-analyses results, we generated fuji plot
655 using R script and Circos software^{55,56}. Then, we used the GWAS meta summary
656 statistics for all the subsequent analyses.

657

658 To identify independent genome-wide significant signals ($P < 5 \times 10^{-8}$), we used
659 GCTA⁵⁷ multi-SNP-based conditional & joint association analysis (COJO¹⁸) with a
660 stepwise model selection (--cojo-slct). Variants with MAF < 0.01 were filtered and
661 the collinearity threshold was 0.2. 500kb upstream and downstream block of a
662 genome-wide significant signal was divided into a separate locus. The SNP with the
663 smallest P value in each locus was selected as the lead SNP. In addition, if the SNP
664 had P value less than 4.1×10^{-10} , it was considered to be a variant that reached the
665 study-wide significance. Similarly, we used the same method to select independent

666 SNPs from the 220 GWAS summary statistics of BBJ cohort¹⁰ and 23 GWAS
667 summary statistics of Taiwan Biobank¹⁹ for subsequent analysis.

668

669 **Replication of independent genome-wide significant signals**

670 To examine whether genetic effects of the same phenotype were equivalent between
671 the two cohorts, we performed internal replication and external comparison of
672 independent genome-wide significant SNPs obtained from conditional analysis using
673 two methods. In the internal replication, we compared the direction of beta and P
674 value of each SNP in the two hospitals. The criteria for a SNP to be replicated were
675 that it had consistent beta direction and the P value was less than the Bonferroni-
676 corrected significant threshold (0.05/number of independent SNPs per phenotype). In
677 the second approach, based on the central limit theorem, we utilized a *two-sample t-*
678 *test* with the following hypotheses:

$$\text{Null hypothesis } H_0: \beta_1 = \beta_2$$

$$\text{Alternative hypothesis } H_1: \beta_1 \neq \beta_2$$

679 The statistic T was calculated as follows:

$$T = \frac{\beta_1 - \beta_2}{\sqrt{SE_1^2 + SE_2^2}} \sim t(v') \quad (1)$$

680 The degrees of freedom v' were calculated by the formula:

$$v' = \frac{(SE_1^2 + SE_2^2)^2}{\frac{SE_1^4}{n_1 - 1} + \frac{SE_2^4}{n_2 - 1}} \quad (2)$$

681 In the formulas, β represents the estimate of the genetic effect, SE represents the
682 standard error of the genetic effect estimate, and N represents the sample size of trait
683 in the cohort. The P value was calculated using the statistic T and degrees of freedom
684 v' obtained from the formulas, and the SNP was replicated successfully if the P value
685 was greater than 0.05. In addition, we used METAL to estimate heterogeneity tests for
686 the genetic effects of SNPs between the two hospitals, and P value ≥ 0.05 were taken

687 to indicate that there was no heterogeneity in the genetic effects of the SNP between
688 the two hospitals.

689

690 We conducted external replication of the identified variants using the NIPT PLUS
691 pregnancy cohort, which is a data collection of 5,733 individuals who sought maternal
692 check-ups at Shenzhen Baoan Women's and Children's Hospital (Shenzhen, China)
693 throughout the entire 40-week gestational period. Between 2020 and 2021, these
694 pregnant women received NIPT in the first or second trimester and provided written
695 informed consent. Besides, these samples were sequenced at a deeper depth compared
696 to traditional NIPT. The genotyping and quality control process of NIPT PLUS cohort
697 participants were the same as Baoan and Longgang. Among the 122 phenotypes in
698 this study, 103 phenotypes could be replicated in the NIPT PLUS pregnancy cohort.
699 We used the same methods as for the internal replication to perform external
700 replication of the variants for these 103 phenotypes.

701

702 **Comparison of genetic effects on maternal height and Taiwanese** 703 **population height**

704 As maternal height is essentially unchanged during pregnancy, we demonstrate the
705 effectiveness of our GWAS results by comparing the genetic effects of height in the
706 Taiwanese population with the genetic effects of maternal height related variants¹⁹.
707 We extracted genome-wide significant independent variants associated with height in
708 Taiwanese population and found corresponding genetic effects in our GWAS
709 summary statistic. Comparisons were made using the Bonferroni correction threshold
710 method and the rate of success in the comparison was calculated.

711

712 **Identification of novel locus and signal**

713 We downloaded all associations (v1.0.2_e109_r2023-02-15) from GWAS Catalog²⁰
714 to identify novel associated SNPs. A trait associated locus was considered novel when

715 the ± 500 kb range of the lead SNP did not include previously reported associations in
716 the GWAS Catalog for the same trait. In addition, we considered a trait-associated
717 signal as novel when it satisfied that the R^2 between the GWAS Catalog reported
718 SNPs and our SNP was less than 0.2. The R^2 calculations were performed on the
719 LDpair Tool through LDlink⁵⁸ (version 5.5.1) based on GRCh38 1000G genome build
720 in the EAS and EUR populations.

721

722 **Protein-protein interaction network analysis**

723 We selected genes hosting loci in our study for protein-protein interaction (PPI)
724 analysis. Genes with PPI score > 0.4 were chosen to build a network model visualized
725 by Cytoscape (Version:3.10.1)⁵⁹. The degree algorithm implemented in CytoHubba⁶⁰
726 was used to compute the top 10 hub genes. Software parameters used default
727 parameters.

728

729 **Genetic heritability and correlation estimates**

730 We standardized the phenotypic data and calculated their Spearman correlation
731 coefficients to obtain the phenotypic correlation matrix. Then the meta GWAS
732 summary statistics were used to estimate SNP-based heritability and genetic
733 correlation (r_g) for all phenotypes using LD Score Regression^{33,61}. GCTA⁶² was used
734 to calculate LD score files using 10,000 Chinese population high-depth sequencing
735 genotype. The genome was chopped into segments with length of 1000kb (--ld-wind
736 1000), and the cutoff for LD R^2 was 0.01 (--ld-rsq-cutoff 0.01). The phenotypic
737 correlation matrix and genetic association matrix of the two hospitals were extracted
738 to draw heat maps, respectively.

739

740 **Detection of pregnancy-specific effects**

741 Because of the paucity of currently available GWAS summary statistics for pregnancy
742 and the influence of population structure, we used GWAS summary statistics for

743 similar phenotypes from the Taiwan Biobank¹⁹, which were downloaded for external
744 comparisons. Three conditions were required for an independent SNP to be compared:
745 1) the SNP was present in the externally compared GWAS summary statistic; 2) the
746 effect allele and the direction of the genetic effect were the same as those of the
747 externally data; and 3) the P value was less than the Bonferroni-corrected threshold
748 (0.05/number of loci).

749

750 We applied `linemodels` package³⁶ (<https://github.com/mjpirinen/linemodels>) to the
751 GWAS summary statistics from gestational phenotypes GWAS and similar
752 phenotypes GWAS in the general population of East Asia. The analysis included
753 1,318 variants in 23 phenotypes (**Supplementary Table 23**). We classified the
754 variants into two clusters based on their effect sizes, pregnancy specific variants and
755 general variants. If the genetic effect of the variant is more different from that of the
756 general population in East Asia, it is called a pregnancy specific variant (posterior
757 probability of pregnancy > 0.95), and if the genetic effect is more consistent between
758 the two, it is called a general variant (posterior probability of general > 0.95). The
759 clusters were represented by line models where the slope of the pregnancy cluster is
760 fixed to 0, the correlations are fixed to 0.999 in both clusters, and the other parameters
761 are estimated using EM algorithm. The parameters of the various categories are
762 shown in **Supplementary Table 23**. The slope represents the slopes of the two lines,
763 and the scale determines the magnitude of effect sizes, and the correlation determines
764 the allowed deviation from the lines.

765

766 To exclude the effect of LD structure on classification, we performed colocalization
767 analyses of variants in gestational phenotypes and variants in East Asian populations
768 with the same or similar phenotypes and adjusted the `linemodels` results depending on
769 colocalization results. We set the prior probability of an SNP associated with
770 phenotypes of pregnant women (p_1) and in East Asia (p_2) as 1×10^{-4} , and the prior

771 probability of an SNP associated with both traits (p_{12}) as 5×10^{-6} ⁶³. We adjusted the
772 classification results by adopting the following criteria. If a variant classified as a
773 pregnancy cluster in line models had a posterior probability (PPH4) < 0.2, the
774 classification result remained unchanged; otherwise, it was classified as an uncertain
775 cluster; if a variant in a general cluster had a PPH4 > 0.8, the classification result
776 remained unchanged; otherwise, it was classified as an uncertain cluster; if a variant
777 classified as a uncertain cluster in line models had a PPH4 < 0.2, it was classified as
778 an pregnancy cluster; if a variant classified as a uncertain cluster in line models had a
779 PPH4 > 0.8, it was classified as an general cluster. The results of the classification of
780 the other cases are consistent with line models.

781

782 **Enrichment analysis of variants**

783 Based on the results of line models, we performed enrichment analysis using
784 Metascape (v3.5.20240101)⁶⁴. This method calculates the hit rate with our gene list
785 and the background hit rate based on the number of genes in each section, and the
786 ratio of the two is the enrichment factor. The *P*-value is defined as the probability of
787 obtaining multiple pathways, forming a cumulative hypergeometric distribution, the
788 more negative the value, the less likely it is that the observed enrichment is due to
789 randomness. The analysis was performed with default parameters, namely, the min
790 overlap was set to 3, the *P* value cutoff was 0.01, the min enrichment factor was 1.5.
791 Ontology category included GO Biological Processes, Reactome Gene Sets, KEGG
792 Pathway, WikiPathways, Canonical Pathways and PANTHER Pathway.

793

794 We performed separate enrichment analyses for genes with pregnancy-specific
795 variants and genes with general variants, selecting the top 20 pathways with the most
796 significant pregnancy-specific variants and comparing them with the general variants.
797 We also aggregated all genes for enrichment analysis of single gene lists.

798

799 Longitudinal trajectories of genetic effects

800 We conducted analyses using TrajGWAS³⁹ to identify genetic variants that contribute
801 to change in gestational phenotypes during pregnancy and postpartum. We used
802 gestational day as a time factor to determine whether there was a genetic-time
803 interaction. GWAS for longitudinal biomarkers was performed using the TrajGWAS
804 method, based on a mixed effects model with the following formula:

$$y_{ij} = x_{ij}\beta + g_i\beta_g + G \times T \times \beta_{G \times T} + \varepsilon_{ij} \quad (3)$$

805 y_{ij} represents the phenotypic value of the j th measurement for the i th pregnant
806 woman. x_{ij} represents fixed-effects covariates, including the first ten principal
807 components, maternal age and gestational days at phenotypic testing, β is its
808 corresponding effect value. g_i denotes the genotype dosage for the i th pregnant
809 woman, corresponding to a genetic effect of β_g . $G \times T$ represents the interaction
810 between maternal genotype dosage and gestational time, corresponding to an effect
811 value of $\beta_{G \times T}$. ε_{ij} is a random-effects term reflecting the variance of the genetic
812 variants affecting the within-subject (WS) variance of the biomarker. The formula for
813 the variance $\sigma_{\varepsilon_{ij}}^2$ of ε_{ij} is given below:

$$\sigma_{\varepsilon_{ij}}^2 = \exp(\tau w_{ij} + \tau_g g_i + \tau_{G \times T} G \times T + \omega_i) \quad (4)$$

814 w_{ij} is a covariate including the first 10 principal components, maternal age, and
815 gestational days at phenotypic measurement, and τ is the corresponding effect value.
816 τ_g denotes the genetic effect affecting the variance of WS. $\tau_{G \times T}$ indicates the effect
817 value for the interaction of maternal genotype dosage and gestational time. ω_i denotes
818 the random intercept.

819

820 There were 24 of these phenotypes, involving phenotypes of the Blood routine
821 categories (N=24). Specific phenotypes are shown in **Supplementary Table 27**.
822 Following the procedure described by Ko et al., we first performed the score test for
823 SNPs, obtaining the direction of the effect (β_g or τ_g) and the P value that affected the
824 mean and within-subject variability for each phenotype. Subsequently, the Wald test

825 was performed on SNPs with a P value of β_g or τ_g less than 5×10^{-8} to estimate the
826 effect sizes of the genetic effect of genotype dosage (β_g or τ_g) and the effect of
827 interaction between maternal genotype dosage and gestational time ($\beta_{G \times T}$ or $\tau_{G \times T}$).
828 Subsequently, we performed a meta-analysis of the effect values of these significant
829 SNPs using METAL⁵⁴. TrajGWAS analyses were performed with the Julia package
830 TrajGWAS.jl (<https://github.com/OpenMendel/TrajGWAS.jl>)⁶⁵. Manhattan and QQ
831 plots in the supplementary figures were drawn with a Julia package MendelPlots.jl
832 (<https://github.com/OpenMendel/MendelPlots.jl>)⁶⁵ with SNP minor allele
833 frequency > 0.01. To identify independent significant loci, we used a python script
834 where the variant with the smallest P value in the 1Mb range was the lead SNP, and
835 variants within 500kb above and below the lead variant were classified into a locus.

836

837 In order to investigate whether the genetic effects of the loci identified by TrajGWAS
838 change during a total of five periods: first, second, and third trimester of pregnancy,
839 day of delivery, and within 42 days postpartum, we performed localized association
840 analyses of these loci. The main steps were consistent with the previous GWAS,
841 except that the PLINK⁵¹ (version 2.0) parameters --chr, --from-bp, and --to-bp were
842 used to point to the loci. We defined a variant with change as a non-overlapping 95%
843 confidence interval (CI) for the genetic effect in at least two of the five periods.

844

845 We enriched the variants with significant genotype dosage for significant and non-
846 significant interactions between genetics and environment. Methods were the same as
847 for the enrichment analyses described above.

848

849 **Mendelian randomization network of pregnancy, Taiwanese and** 850 **BBJ traits**

851 To identify whether pregnancy status affects the development of future disease
852 progression, bidirectional mendelian randomization analyses were performed on

853 cohort of this study and Japanese Biobank cohort data with the TwoSampleMR
854 package^{66,67}. We used GWAS summary statistics from two cohorts and independent
855 SNPs obtained from GCTA-COJO as genetic instruments ($P < 5 \times 10^{-8}$) in our MR
856 analyses. We also calculated the proportion of variance in phenotypes explained (PVE)
857 by the instruments according to the formula⁶⁸ (3) and calculated the F-statistic
858 according to formula (4) to evaluate the strength of instruments, with F values greater
859 than 10 indicating sufficient strength.

$$PVE = \frac{2\hat{\beta}^2 MAF(1 - MAF)}{2\hat{\beta}^2 MAF(1 - MAF) + (se(\hat{\beta}))^2 2NMAF(1 - MAF)} \quad (5)$$

$$F = \frac{N - nsnp - 1}{nsnp} \times \frac{PVE}{1 - PVE} \quad (6)$$

860 The assessments of the instrumental variables are shown in the **Supplementary**
861 **Table 36-39**. We conducted sensitivity analyses using alternative MR methods that
862 including: 1) MR Egger; 2) Simple mode; 3) Weighted median; 4) Weighted mode.
863 Among the several methods of MR analyses, the inverse variance weight (IVW)
864 method which confers the greatest statistical power for estimating causal associations
865 was used as primary reference⁶⁹.

866

867 To examine and address horizontal pleiotropy in causal relationships inferred from
868 MR analyses, we performed MR-PRESSO⁴⁰ using the results of the first two-sample
869 MR. The outliers were found using MR-PRESSO and tested for differences between
870 the pre-correction and post-correction results. The outliers would be excluded, and the
871 two-sample MR was performed again if the difference was significant.

872

873 Robust causal estimates were defined as those that were significant at FDR q value of
874 IVW⁷⁰ ($q < 0.01$) and showed no evidence of heterogeneity ($P > 0.05$) and horizontal
875 pleiotropy ($P > 0.05$) after MR-PRESSO.

876

877 We also performed two-sample MR of 23 Taiwanese phenotypes with 220 BBJ
878 phenotypes. The methodology is the same as in the previous section. Genetic
879 instrumental variable information is displayed in **Supplementary Table 43-44**.

880

881 To adjust for the influence of mid-life health status on causal relationships, we
882 incorporated 23 phenotypes from the Taiwan Biobank¹⁹ as a second exposure in the
883 multivariable mendelian randomization analysis^{71,72}. The gestational phenotype and
884 the Taiwan Biobank phenotype were used as exposures, and the 220 phenotypes from
885 the BBJ were used as outcomes. We also used the TwoSampleMR package. The
886 significance threshold is $q < 0.01$.

887

888

889

890

891

892

893

894 Reference

- 895 1. Stock, S.J. & Aiken, C.E. Barriers to progress in pregnancy research: How can
896 we break through? *Science* **380**, 150-153 (2023).
- 897 2. Qiao, J. *et al.* A Lancet Commission on 70 years of women's reproductive,
898 maternal, newborn, child, and adolescent health in China. *Lancet* **397**, 2497-
899 2536 (2021).
- 900 3. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE),
901 and population estimates in 204 countries and territories, 1950-2019: a
902 comprehensive demographic analysis for the Global Burden of Disease Study
903 2019. *Lancet* **396**, 1160-1203 (2020).
- 904 4. Chen, X. *et al.* The path to healthy ageing in China: a Peking University-
905 Lancet Commission. *Lancet* **400**, 1967-2006 (2022).
- 906 5. Yu, D. *et al.* A multi-tissue metabolome atlas of primate pregnancy. *Cell* **187**,
907 764-781.e14 (2024).
- 908 6. Hunter, P.J. *et al.* Biological and pathological mechanisms leading to the birth
909 of a small vulnerable newborn. *Lancet* **401**, 1720-1732 (2023).
- 910 7. Liu, S. *et al.* Genomic Analyses from Non-invasive Prenatal Testing Reveal
911 Genetic Associations, Patterns of Viral Infections, and Chinese Population
912 History. *Cell* **175**, 347-359.e14 (2018).
- 913 8. Zhen, J. *et al.* Genome-wide association and Mendelian randomisation
914 analysis among 30,699 Chinese pregnant women identifies novel genetic and
915 molecular risk factors for gestational diabetes and glycaemic traits.
916 *Diabetologia* **67**, 703-713 (2024).
- 917 9. Yang, Z. *et al.* Genetic Basis of Altered Platelet Counts and Gestational
918 Thrombocytopenia in Pregnancy. *Blood* (2023).
- 919 10. Sakaue, S. *et al.* A cross-population atlas of genetic associations for 220
920 human phenotypes. *Nat Genet* **53**, 1415-1424 (2021).

- 921 11. Graham, S.E. *et al.* The power of genetic diversity in genome-wide association
922 studies of lipids. *Nature* **600**, 675-679 (2021).
- 923 12. Elliott, A. *et al.* Distinct and shared genetic architectures of gestational
924 diabetes mellitus and type 2 diabetes. *Nat Genet* **56**, 377-382 (2024).
- 925 13. Juliusdottir, T. *et al.* Distinction between the effects of parental and fetal
926 genomes on fetal growth. *Nat Genet* **53**, 1135-1142 (2021).
- 927 14. Huang, S. *et al.* The Born in Guangzhou Cohort Study enables generational
928 genetic discoveries. *Nature* **626**, 565-573 (2024).
- 929 15. Mitha, A. *et al.* Neurological development in children born moderately or late
930 preterm: national cohort study. *Bmj* **384**, e075630 (2024).
- 931 16. Crump, C. *et al.* Adverse pregnancy outcomes and long term risk of ischemic
932 heart disease in mothers: national cohort and co-sibling study. *Bmj* **380**,
933 e072112 (2023).
- 934 17. Liu, S. *et al.* Utilizing Non-Invasive Prenatal Test Sequencing Data Resource
935 for Human Genetic Investigation. *bioRxiv*, 2023.12. 11.570976 (2023).
- 936 18. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS
937 summary statistics identifies additional variants influencing complex traits.
938 *Nat Genet* **44**, 369-75, s1-3 (2012).
- 939 19. Chen, C.Y. *et al.* Analysis across Taiwan Biobank, Biobank Japan, and UK
940 Biobank identifies hundreds of novel loci for 36 quantitative traits. *Cell*
941 *Genom* **3**, 100436 (2023).
- 942 20. Sallis, E. *et al.* The NHGRI-EBI GWAS Catalog: knowledgebase and
943 deposition resource. *Nucleic Acids Res* **51**, D977-d985 (2023).
- 944 21. Kelleher, A.M., DeMayo, F.J. & Spencer, T.E. Uterine Glands:
945 Developmental Biology and Functional Roles in Pregnancy. *Endocr Rev* **40**,
946 1424-1445 (2019).
- 947 22. Mills, M.C. *et al.* Identification of 371 genetic variants for age at first sex and
948 birth linked to externalising behaviour. *Nat Hum Behav* **5**, 1717-1730 (2021).

- 949 23. Gibson, D.A. *et al.* Profiling the expression and function of oestrogen receptor
950 isoform ER46 in human endometrial tissues and uterine natural killer cells.
951 *Hum Reprod* **35**, 641-651 (2020).
- 952 24. Schlaikjær Hartwig, T. *et al.* Cell-free fetal DNA for genetic evaluation in
953 Copenhagen Pregnancy Loss Study (COPL): a prospective cohort study.
954 *Lancet* **401**, 762-771 (2023).
- 955 25. Chitty, L.S. Use of cell-free DNA to screen for Down's syndrome. *N Engl J*
956 *Med* **372**, 1666-7 (2015).
- 957 26. Wang, W. *et al.* Homozygous variants in PANX1 cause human oocyte death
958 and female infertility. *Eur J Hum Genet* **29**, 1396-1404 (2021).
- 959 27. Sang, Q. *et al.* A pannexin 1 channelopathy causes human oocyte death. *Sci*
960 *Transl Med* **11**(2019).
- 961 28. Brinkmann, V. *et al.* Neutrophil extracellular traps kill bacteria. *Science* **303**,
962 1532-5 (2004).
- 963 29. Bouvier, S. *et al.* NETosis Markers in Pregnancy: Effects Differ According to
964 Histone Subtypes. *Thromb Haemost* **121**, 877-890 (2021).
- 965 30. Guillotin, F. *et al.* Vital NETosis vs. suicidal NETosis during normal
966 pregnancy and preeclampsia. *Front Cell Dev Biol* **10**, 1099038 (2022).
- 967 31. Yu, G. *et al.* APRIL and TALL-I and receptors BCMA and TACI: system for
968 regulating humoral immunity. *Nat Immunol* **1**, 252-6 (2000).
- 969 32. Duan, T. *et al.* USP3 plays a critical role in the induction of innate immune
970 tolerance. *EMBO Rep* **24**, e57828 (2023).
- 971 33. Bulik-Sullivan, B.K. *et al.* LD Score regression distinguishes confounding
972 from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-5
973 (2015).
- 974 34. lab, N. UK Biobank-Neale lab. (2018).
- 975 35. Dalmia, A. *et al.* A genetic epidemiological study in British adults and older
976 adults shows a high heritability of the combined indicator of vitamin B(12)

- 977 status (cB(12)) and connects B(12) status with utilization of mitochondrial
978 substrates and energy metabolism. *J Nutr Biochem* **70**, 156-163 (2019).
- 979 36. Pirinen, M. linemodls: clustering effects based on linear relationships.
980 *Bioinformatics* **39**(2023).
- 981 37. Li, A., Yang, S., Zhang, J. & Qiao, R. Establishment of reference intervals for
982 complete blood count parameters during normal pregnancy in Beijing. *J Clin*
983 *Lab Anal* **31**(2017).
- 984 38. Zhu, J., Li, Z., Deng, Y., Lan, L. & Yang, J. Comprehensive reference
985 intervals for white blood cell counts during pregnancy. *BMC Pregnancy*
986 *Childbirth* **24**, 35 (2024).
- 987 39. Ko, S. *et al.* GWAS of longitudinal trajectories at biobank scale. *Am J Hum*
988 *Genet* **109**, 433-445 (2022).
- 989 40. Verbanck, M., Chen, C.Y., Neale, B. & Do, R. Detection of widespread
990 horizontal pleiotropy in causal relationships inferred from Mendelian
991 randomization between complex traits and diseases. *Nat Genet* **50**, 693-698
992 (2018).
- 993 41. Bonaca, M.P., Hamburg, N.M. & Creager, M.A. Contemporary Medical
994 Management of Peripheral Artery Disease. *Circ Res* **128**, 1868-1884 (2021).
- 995 42. Ranaei Pirmardan, E. *et al.* Pre-hyperglycemia immune cell trafficking
996 underlies subclinical diabetic cataractogenesis. *J Biomed Sci* **30**, 6 (2023).
- 997 43. Jonasson, L., Tompa, A. & Wikby, A. Expansion of peripheral CD8+ T cells
998 in patients with coronary artery disease: relation to cytomegalovirus infection.
999 *J Intern Med* **254**, 472-8 (2003).
- 1000 44. Borgia, M.C. *et al.* Further evidence against the implication of active
1001 cytomegalovirus infection in vascular atherosclerotic diseases. *Atherosclerosis*
1002 **157**, 457-62 (2001).
- 1003 45. Parikh, N.I. *et al.* Adverse Pregnancy Outcomes and Cardiovascular Disease
1004 Risk: Unique Opportunities for Cardiovascular Disease Prevention in Women:

- 1005 A Scientific Statement From the American Heart Association. *Circulation* **143**,
1006 e902-e916 (2021).
- 1007 46. Auger, N., Tang, T., Healy-Profitós, J. & Paradis, G. Gestational diabetes and
1008 the long-term risk of cataract surgery: A longitudinal cohort study. *J Diabetes*
1009 *Complications* **31**, 1565-1570 (2017).
- 1010 47. Patel, R.R., Steer, P., Doyle, P., Little, M.P. & Elliott, P. Does gestation vary
1011 by ethnic group? A London-based study of over 122,000 pregnancies with
1012 spontaneous onset of labour. *Int J Epidemiol* **33**, 107-113 (2004).
- 1013 48. Cheung, S.W., Patel, A. & Leung, T.Y. Accurate description of DNA-based
1014 noninvasive prenatal screening. *N Engl J Med* **372**, 1675-7 (2015).
- 1015 49. Rubinacci, S., Ribeiro, D.M., Hofmeister, R.J. & Delaneau, O. Efficient
1016 phasing and imputation of low-coverage sequencing data using large reference
1017 panels. *Nature Genetics* **53**, 120-126 (2021).
- 1018 50. Cheng, S. *et al.* The STROMICS genome study: deep whole-genome
1019 sequencing and analysis of 10K Chinese patients with ischemic stroke reveal
1020 complex genetic and phenotypic interplay. *Cell Discov* **9**, 75 (2023).
- 1021 51. Chang, C.C. *et al.* Second-generation PLINK: rising to the challenge of larger
1022 and richer datasets. *Gigascience* **4**, 7 (2015).
- 1023 52. Meisner, J., Liu, S., Huang, M. & Albrechtsen, A. Large-scale inference of
1024 population structure in presence of missingness using PCA. *Bioinformatics* **37**,
1025 1868-1875 (2021).
- 1026 53. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* **17**,
1027 122 (2016).
- 1028 54. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis
1029 of genomewide association scans. *Bioinformatics* **26**, 2190-2191 (2010).
- 1030 55. Krzywinski, M. *et al.* Circos: an information aesthetic for comparative
1031 genomics. *Genome Res* **19**, 1639-45 (2009).

- 1032 56. Kanai, M. *et al.* Genetic analysis of quantitative traits in the Japanese
1033 population links cell types to complex human diseases. *Nat Genet* **50**, 390-400
1034 (2018).
- 1035 57. Yang, J., Lee, S.H., Goddard, M.E. & Visscher, P.M. GCTA: A Tool for
1036 Genome-wide Complex Trait Analysis. *The American Journal of Human*
1037 *Genetics* **88**, 76-82 (2011).
- 1038 58. Machiela, M.J. & Chanock, S.J. LDlink: a web-based application for exploring
1039 population-specific haplotype structure and linking correlated alleles of
1040 possible functional variants. *Bioinformatics* **31**, 3555-7 (2015).
- 1041 59. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of
1042 biomolecular interaction networks. *Genome Res* **13**, 2498-504 (2003).
- 1043 60. Chin, C.-H. *et al.* cytoHubba: identifying hub objects and sub-networks from
1044 complex interactome. *BMC Systems Biology* **8**, S11 (2014).
- 1045 61. Bulik-Sullivan, B. *et al.* An atlas of genetic correlations across human diseases
1046 and traits. *Nat Genet* **47**, 1236-41 (2015).
- 1047 62. Yang, J. *et al.* Genetic variance estimation with imputed variants finds
1048 negligible missing heritability for human height and body mass index. *Nat*
1049 *Genet* **47**, 1114-20 (2015).
- 1050 63. Wallace, C. Eliciting priors and relaxing the single causal variant assumption
1051 in colocalisation analyses. *PLoS Genet* **16**, e1008720 (2020).
- 1052 64. Zhou, Y. *et al.* Metascape provides a biologist-oriented resource for the
1053 analysis of systems-level datasets. *Nat Commun* **10**, 1523 (2019).
- 1054 65. Zhou, H. *et al.* OPENMENDEL: a cooperative programming project for
1055 statistical genetics. *Hum Genet* **139**, 61-71 (2020).
- 1056 66. Hemani, G. *et al.* The MR-Base platform supports systematic causal inference
1057 across the human phenome. *eLife* **7**(2018).

- 1058 67. Li, J., Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal
1059 relationship between imprecisely measured traits using GWAS summary data.
1060 *PLOS Genetics* **13**(2017).
- 1061 68. Teslovich, T.M. *et al.* Biological, clinical and population relevance of 95 loci
1062 for blood lipids. *Nature* **466**, 707-13 (2010).
- 1063 69. Slob, E.A.W. & Burgess, S. A comparison of robust Mendelian randomization
1064 methods using summary data. *Genetic Epidemiology* **44**, 313-329 (2020).
- 1065 70. John D. Storey, A.J.B., Alan Dabney, David Robinson. qvalue: Q-value
1066 estimation for false discovery rate control. R package version 2.36.0 (2024).
- 1067 71. Sanderson, E. Multivariable Mendelian Randomization and Mediation. *Cold
1068 Spring Harb Perspect Med* **11**(2021).
- 1069 72. Vabistsevits, M. Setting up Multivariable Mendelian Randomization analysis
1070 in R. (22 March, 2021).
- 1071
- 1072

1073 **Figure Legends**

1074 **Figure 1. Schematic overview of the study.**

1075 We curated a comprehensive dataset comprising 122 pregnancy-related phenotypes
1076 from 120,579 Chinese pregnant women. We conducted an in-depth analysis of the
1077 genetic architecture underlying these phenotypes, identified biological pathways
1078 enriched for genetic variants, and explored genetic variants associated with alterations
1079 in the longitudinal trajectories of these phenotypes. Additionally, we investigated
1080 potential causal relationships between gestational phenotypes and various diseases.

1081

1082 **Figure 2. Genetic associations with nine categories of gestational** 1083 **phenotypes.**

1084 The top-left inset presents a histogram depicting the number of loci associated with
1085 gestational phenotypes for each trait, categorized into novel and known loci. In the
1086 main panel, a Fuji plot illustrates the results of the genome-wide association analysis
1087 (GWAS) across all phenotypes within nine categories. Independent variants identified
1088 through meta-analysis ($P < 4.1 \times 10^{-10}$) are shown. The number of associated
1089 phenotypes per pleiotropic locus is represented by filled colored boxes, with
1090 functional and newly discovered loci labeled directly on the plot. Detailed information
1091 on functional loci can be found in Supplementary Table 15. Pleiotropic and trait-
1092 specific associations are distinguished by circles of varying sizes. The order of the 88
1093 gestational phenotypes in both the histogram and Fuji plot corresponds to that in
1094 Supplementary Table 2.

1095

1096 **Figure 3. Classification of the genetic effects of SNPs on gestational** 1097 **phenotypes and Taiwan Biobank phenotypes, along with the** 1098 **identification of pathways enriched for pregnancy specific and** 1099 **general variants.**

1100 Panel **A** presents a plot classifying the genetic effects of SNPs ($P < 4.1 \times 10^{-10}$,
1101 Bonferroni correction threshold) on gestational phenotypes, utilizing a Bayesian
1102 classification algorithm and colocalization analysis. Panel **B** features a butterfly bar
1103 plot illustrating the top 20 most significant pathways for pregnancy-specific variants,
1104 identified through Metascape enrichment analysis. On the left side, the plot shows the
1105 enrichment P values for pregnancy-specific variants and the percentage of genes
1106 enriched in each pathway relative to the total number of pregnancy-specific genes.
1107 The right side displays the corresponding results for general variants. Pathways
1108 showing significant differences in gene enrichment, as determined by a chi-square test,
1109 are marked with an asterisk (*).

1110

1111 **Figure 4. Results of trajectory changes in blood cell traits during**
1112 **pregnancy.**

1113 Panel **A** presents forest plots illustrating the genetic effects across five time periods
1114 with significant genetic and environmental interactions for the first 25 variants, as
1115 well as for at least two of the five periods where no overlap in genetic effects was
1116 observed. Different colors represent each period, indicating beta values and 95%
1117 confidence intervals, with annotations highlighting whether the variant has a P -value
1118 less than 5×10^{-8} . The eQTL status of each variant is indicated adjacent to the
1119 variant label. Detailed information can be found in Supplementary Table 31. Panel **B**
1120 depicts changes in white blood cell (WBC) counts across the first, second, and third
1121 trimesters, at delivery, and during the postpartum period, based on data from two
1122 hospitals. A generalized additive model was used to smooth the curve, with the ribbon
1123 around the curve representing the 95% confidence interval. The first trimester spans
1124 from conception to 14 weeks (98 days), the second trimester covers weeks 14 through
1125 28 (196 days), and the third trimester extends from week 28 to delivery. Panel **C**
1126 displays a forest plot of the genetic effect of the rs2270401-A allele at 17q21.1
1127 (*MED24*) on WBC counts, based on a meta-analysis across the first, second, and third

1128 trimesters, at delivery, and postpartum. Points represent the genetic effect (beta), with
1129 error bars indicating the 95% confidence interval. Panel **D** presents the results of
1130 enrichment analyses for variants showing significant and non-significant genetic and
1131 environmental interactions.

1132 BASO: basophil absolute value; BASO_P: basophil percentage; HGB: hemoglobin
1133 level; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin;
1134 RDW_CV: red blood cell volume distribution width variation; PLT: platelet count;
1135 MPV: mean platelet volume; PCT: platelet crit; PDW: platelet distribution width;
1136 P_LCR: platelet-large cell ratio.

1137

1138 **Figure 5. Causal inferences between pregnancy-related phenotypes**
1139 **and BBJ phenotypes.**

1140 Panel **A** displays bidirectional Mendelian Randomization (MR) estimates, illustrating
1141 causal links between all pregnancy-related phenotypes (blue nodes) and traits from
1142 the Biobank Japan (BBJ) cohort (red nodes). Arrows indicate the direction of
1143 association, with red denoting an increasing effect and blue representing a decreasing
1144 effect. Panel **B** features a heatmap of MR results, showing nine categories of
1145 gestational phenotypes as the exposures (right) and BBJ phenotypes as the outcomes
1146 (bottom). Relationships with P values below the false discovery rate (FDR) threshold
1147 are annotated with an asterisk (*, $q < 0.01$). Panel **C** presents an MR scatterplot
1148 where maternal triglyceride (TG) levels serve as the exposure and the use of
1149 antithrombotic agents in the BBJ cohort as the outcome. Panel **D** shows an MR
1150 scatterplot with maternal oral glucose tolerance test 1-hour plasma glucose (OGTT1H)
1151 levels as the exposure, and peripheral artery disease in the BBJ cohort as the outcome.

Study Cohort



Genotype

Genome sequencing from NIPT
N=121,579



Phenotypes

Blood lipid & Glycemic (N=8)
Blood routine (N=32)
Infection (N=14)
Liver, Kidney & Thyroid function (N=15)
Tang & NIPT screen (N=19)

Basic information (N=7)
Birth outcome (N=6)
Gestational disorders (N=21)

Genetic association

Baoan
(N=50,963)

Longgang
(N=70,616)



5,027 independent signals in 3,845 loci

Consistency
Baoan vs Longgang
(N=121,579)

External replication
NIPT PLUS
(N=5,733)

Genome-wide association study

24 gestational phenotypes with multiple measurements in 5 periods


TrajGWAS

localized association

GWAS of longitudinal trajectories

Post-GWAS


Heritability & Correlation



LDSC


Up to 44% heritability

Different variant analysis



Genetic difference

Mendelian randomization









TwoSample MR & Multivariable MR




Future health

A

Gestational phenotypes

**B**



A**B****C****D**